Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Mark N. Levine

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1288-0773; OpenAlex author ID A5013493617. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug. Co-author DOI 10.1016/j.freeradbiomed.2024.07.008↗
  2. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Last author DOI 10.1371/journal.pone.0029794↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jeffrey Brender · 1 shared paper, 2024 · strength 0.22
  2. William Marston Linehan · 1 shared paper, 2024 · strength 0.22
  3. Yasunori Otowa · 1 shared paper, 2024 · strength 0.22
  4. Kazutoshi Yamamoto · 1 shared paper, 2024 · strength 0.22
  5. Shun Kishimoto · 1 shared paper, 2024 · strength 0.22
  6. Murali Cherukuri Krishna · 1 shared paper, 2024 · strength 0.22
  7. Daniel R. Crooks · 1 shared paper, 2024 · strength 0.22
  8. Daniel Monti · 1 shared paper, 2012 · strength 0.03
  9. Edith Peterson Mitchell · 1 shared paper, 2012 · strength 0.03
  10. Charles J. Yeo · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.